| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis? |
| Autor/-in: | Wang, Z. Chen, C. Finger, S. N. Kwajah M.M, S. d/o Jung, M. Schwarz, H. Swanson, N. Lareu, R. R. Raghunath, M. |
| DOI: | 10.1183/09031936.00084808 |
| Erschienen in: | The European Respiratory Journal |
| Band(Heft): | 34 |
| Heft: | 1 |
| Seite(n): | 145 |
| Seiten bis: | 155 |
| Erscheinungsdatum: | 2009 |
| Verlag / Hrsg. Institution: | European Respiratory Society |
| ISSN: | 0903-1936 1399-3003 |
| Sprache: | Englisch |
| Fachgebiet (DDC): | 615: Pharmakologie und Therapeutik 616: Innere Medizin und Krankheiten |
| Zusammenfassung: | Pulmonary fibrosis represents a fatal stage of interstitial lung diseases of known and idiopathic aetiology. No effective therapy is currently available. Based on an indication-discovery approach we present novel in vitro evidence that the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA), an FDA approved anti-cancer drug, has antifibrotic and anti-inflammatory potential. Human lung fibroblasts (fetal, adult and idiopathic adult pulmonary fibrosis) were treated with transforming growth factor (TGF)-β1 with or without SAHA. Collagen deposition, α-smooth muscle actin (α-SMA) expression, matrix metalloproteinase (MMP)1 activity, tissue inhibitor of MMP (TIMP)1 production, apoptosis and cell proliferation were assessed. Pro-inflammatory cytokines relevant to pulmonary fibrosis were assayed in SAHA-treated human peripheral blood mononuclear cells (PBMC) and its subpopulations. SAHA abrogated TGF-β1 effects on all the fibroblast lines by preventing their transdifferentiation into α-SMA positive myofibroblasts and increased collagen deposition without inducing apoptosis. However, MMP1 activity and TIMP1 production was modulated without a clear fibrolytic effect. SAHA also inhibited serum-induced proliferation of the fibroblast lines and caused hyperacetylation of α-tubulin and histone. Cytokine secretion was inhibited from PBMC and lymphocytes at nonapoptotic concentrations. Taken together, these data demonstrate combined antifibrotic and anti-inflammatory properties of SAHA, suggesting its therapeutic potential for pulmonary fibrosis. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/12201 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Lizenz gemäss Verlagsvertrag |
| Departement: | Life Sciences und Facility Management |
| Organisationseinheit: | Institut für Chemie und Biotechnologie (ICBT) |
| Enthalten in den Sammlungen: | Publikationen Life Sciences und Facility Management |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Wang, Z., Chen, C., Finger, S. N., Kwajah M.M, S. d., Jung, M., Schwarz, H., Swanson, N., Lareu, R. R., & Raghunath, M. (2009). Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis? The European Respiratory Journal, 34(1), 145–155. https://doi.org/10.1183/09031936.00084808
Wang, Z. et al. (2009) ‘Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis?’, The European Respiratory Journal, 34(1), pp. 145–155. Available at: https://doi.org/10.1183/09031936.00084808.
Z. Wang et al., “Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis?,” The European Respiratory Journal, vol. 34, no. 1, pp. 145–155, 2009, doi: 10.1183/09031936.00084808.
WANG, Z., C. CHEN, S. N. FINGER, S. d/o KWAJAH M.M, M. JUNG, H. SCHWARZ, N. SWANSON, R. R. LAREU und M. RAGHUNATH, 2009. Suberoylanilide hydroxamic acid : a potential epigenetic therapeutic agent for lung fibrosis? The European Respiratory Journal. 2009. Bd. 34, Nr. 1, S. 145–155. DOI 10.1183/09031936.00084808
Wang, Z., C. Chen, S. N. Finger, S. d/o Kwajah M.M, M. Jung, H. Schwarz, N. Swanson, R. R. Lareu, and M. Raghunath. 2009. “Suberoylanilide Hydroxamic Acid : A Potential Epigenetic Therapeutic Agent for Lung Fibrosis?” The European Respiratory Journal 34 (1): 145–55. https://doi.org/10.1183/09031936.00084808.
Wang, Z., et al. “Suberoylanilide Hydroxamic Acid : A Potential Epigenetic Therapeutic Agent for Lung Fibrosis?” The European Respiratory Journal, vol. 34, no. 1, 2009, pp. 145–55, https://doi.org/10.1183/09031936.00084808.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.